Tourmaline Bio

New York, United States Founded: 2021 • Age: 5 yrs Listed Acquired By Novartis
Therapeutics for immune disorders are developed by Tourmaline Bio.

About Tourmaline Bio

Tourmaline Bio is a publicly listed company based in New York (United States) founded in 2021, and was acquired by Novartis in September 2025. Therapeutics for immune disorders are developed by Tourmaline Bio. It operates on a HealthTech model. Tourmaline Bio offers products and services including Transformative Medicines. Its focus areas include Biotechnology and Inflammatory and Immune Diseases. Its legal entity is Tourmaline Bio, Inc. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.

Company details

Tourmaline Bio is focused on the development of transformative medicines aimed at establishing new standards of care for patients with life-altering inflammatory and immune diseases. The company operates in the healthcare sector, specifically targeting areas with high unmet medical needs. Solutions are crafted by a dedicated team of entrepreneurs, physicians, and industry experts committed to advancing patient care through innovative pharmaceutical approaches.

  • Headquarters New York, United States
  • Stage Public
  • Sectors
    Healthcare
  • Website tourmalinebio.com
  • Social LinkedIn
  • Acquired by Novartis (Sep 2025)
  • Legal Name Tourmaline Bio, Inc.
Key Metrics
  • Net Profit
    -$73.21 M (USD)
    -73.8
    as on Dec 31, 2024
  • EBITDA
    -$89.69 M (USD)
    -97.67
    as on Dec 31, 2024
  • Investors
  • Acquired by
    Novartis

    (Sep 2025)

Products & Services of Tourmaline Bio

Tourmaline Bio offers a comprehensive portfolio of products and services, including Transformative Medicines.

Transformative Medicines
Pharmaceuticals

Medicines are developed for inflammatory and immune diseases.

Investors in Tourmaline Bio

Tourmaline Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novartis.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
R&D focused on manufacturing of drugs for multiple therapeutic areas
1996novartis.comBasel, Switzerland
Premium access

Investor details for Tourmaline Bio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Tourmaline Bio

36 people are tracked at Tourmaline Bio (25 in leadership, 11 in team).

NameRoleGroup
Christopher Brown
Senior Director Of Technical OperationsLeadership
Ryan Robinson
Chief Financial Officer & TreasurerLeadership
Sandeep Kulkarni
Chief Executive OfficerLeadership
Carole Koveleski
Director, Quality ComplianceLeadership
Alex Meyer
Senior Director Of People, Culture And ComplianceLeadership
Susan D. Jones
Chief Technology OfficerLeadership
Brad Middlekauff
Chief Business Officer And General CounselLeadership
Susan Dana Jones
Chief Technology OfficerLeadership
Gerhard Hagn
Chief Commercial Officer (cco) Heading Commercial And Business DevelopmentLeadership
Clarissa Wheeler
Associate Director, Clinical Trial LiaisonLeadership
Chris Beans
Head Of ITLeadership
Tory Trippe
Senior Director, Finance And Corporate DevelopmentLeadership
Ryan Iarrobino
Senior Vice President, Product DevelopmentLeadership
Monica Louie
Director, Cmc, Quality AssuranceLeadership
Famina Hemani
Vice President, Head Of PharmacovigilanceLeadership
Dora Rau
Senior Vice President, Head Of QualityLeadership
Frances Bai
Director Program ManagementLeadership
Jennessa M.
DirectorLeadership
Aminah Sayid
Associate Director, People & CultureLeadership
Eric Nord
Associate Director Of Analytical DevelopmentLeadership

16 more people are available in the full profile.

Premium access

Complete people profiles for Tourmaline Bio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Tourmaline Bio

Tourmaline Bio is a publicly listed company on the NASDAQ with ticker symbol TRML in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNASDAQ: TRML
  • Listed entityTourmaline Bio, Inc.
  • Exchange sectorHealth technology
  • Share price$47.74 (+0.04% on the day) · 2025-09-29
  • Market capitalisation$1.23B
  • EPS (diluted, trailing year)$-3.44
  • Volume (last session)963,516
  • Analyst consensusNeutral

Financials of Tourmaline Bio

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2024-$73.2M-$89.7M
2023-$42.1M-$45.4M
2022-$19.7M-$19.7M
2021-$47.8M-$46.9M
Premium access

Detailed financial statements for Tourmaline Bio

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Tourmaline Bio

2 dated milestones of Tourmaline Bio across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded Tourmaline Bio is founded.
  2. Exit Acquired by Novartis.

Competitors of Tourmaline Bio

Tourmaline Bio has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
biogen.com1978Cambridge, United States$80M1
Therapies for neurodegenerative and immunology disorders are developed.
admabiologics.com2005Ramsey, United States$17.55M498
Plasma-based biologics are developed for immune deficiency and infectious diseases.
kymeratx.com2016Cambridge, United States$197M150
Small molecule protein degraders are developed for various disorders.
Premium access

Detailed competitors of Tourmaline Bio

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Tourmaline Bio

The website of Tourmaline Bio (tourmalinebio.com) receives about 3.5K visits a month.

  • Monthly visits
    3.5K

    ▼ 7.6% vs previous month

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Tourmaline Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tourmaline Bio

Premium access

Complete news archive for Tourmaline Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tourmaline Bio

Tourmaline Bio was founded in 2021.

Tourmaline Bio is headquartered in New York, United States. It is registered at New York, New York, United States.

Tourmaline Bio is focused on the development of transformative medicines aimed at establishing new standards of care for patients with life-altering inflammatory and immune diseases. The company operates in the healthcare sector, specifically targeting areas with high unmet medical needs. Solutions are crafted by a dedicated team of entrepreneurs, physicians, and industry experts committed to advancing patient care through innovative pharmaceutical approaches.

Tourmaline Bio's top competitors include ADMA Biologics, Kymeratx and Biogen.

Tourmaline Bio offers Transformative Medicines.

Yes, Tourmaline Bio is publicly traded on NASDAQ under the ticker symbol TRML.

Tourmaline Bio has 1 investor. Key investors include Novartis.

Tourmaline Bio operates through Tourmaline Bio, Inc..

Yes. Tourmaline Bio was acquired by Novartis in September 2025.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available